Peripheral Vascular Devices Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Peripheral Vascular Devices Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)


The global peripheral vascular devices market is on an upward trajectory, projected to propel it to a valuation of US$ 8.6 billion by the end of 2031, according to the latest report by Fairfield Market Research. In 2024, the market generated revenues of US$ 4.9 billion, with peripheral vascular stents accounting for a substantial portion.

Increased Volume of Surgeries & Accessibility to Reimbursements Driving Growth

One of the key factors driving the expansion of the peripheral vascular devices market is the increasing volume of surgeries and improved access to reimbursements. The rise in outpatient procedures for peripheral vascular interventions, particularly in developed countries, is attributed to modifications in reimbursement policies and government initiatives. This trend is expected to continue, fostering market growth.

Rising Number of End Users Fueling Market Expansion

The market is further buoyed by the growing number of ambulatory surgical centers (ASCs) in both underdeveloped and developing nations. The proliferation of ASCs is expected to lead to an increase in outpatient cases, thereby driving overall market expansion.

Challenges Due to Product Recalls

While the peripheral vascular devices market is on an upward trajectory, challenges exist, including an increasing threat of product recalls. The development of new and innovative technologies has led to some products being recalled by regulatory bodies like the Food and Drug Administration (FDA) due to serious adverse health consequences. Factors such as deployment issues, bleeding, and strokes pose potential risks and may restrain market growth to some extent.

Country-wise Insights: The U.S., Germany, and China
• The Lucrative U.S. Market: The United States accounted for 94.5% of the North American peripheral vascular devices market. The U.S. market benefits from ongoing development, innovation in technology, and the growing use of drug-eluting stents in interventional procedures.
• Germany's Stance: Germany held a significant share in the European peripheral vascular devices market. The country's focus on research and development, coupled with its quick adoption of healthcare technologies, positions it as a prominent player in the market.
• China Emerges Strong: China dominated the East Asia peripheral vascular devices market. The rising prevalence of diabetes and an aging population in China are driving the demand for peripheral vascular devices.

Competitive Analysis and Key Players

Leading manufacturers in the peripheral vascular devices industry are actively developing technologically-advanced products to strengthen their global portfolios. Mergers, acquisitions, expansions, and collaborations are common strategies employed by key players to enhance their market share.

Key Companies Profiled:
• Abbott Laboratories
• Boston Scientific Corporation
• Cook Medical Inc.
• MicroPort Scientific Corporation (Endovastec™)
• Medtronic Plc.
• Cardinal Health, Inc.
• B. Braun Melsungen AG
• BIOTRONIK SE & Co. KG
• Becton, Dickinson and Company
• W. L. Gore & Associates Inc.
• Getinge AB
• Terumo Corp
• Kyoto Medical Planning Co Ltd
• iVascular S.L.U
• AMG International GmbH
• ENDOCOR GmbH
• Meril Life Sciences Pvt. Ltd.
• Nano Therapeutics Pvt Ltd
• Koninklijke Philips N.V.
• REVA Medical

Peripheral Vascular Devices Industry Research Segmentation

By Product:
• Peripheral Vascular Stents
Self-Expanding Stents
Balloon Expanding Stents
Covered Stents
Drug Eluting Stents
• Drug Eluting Balloons
• Peripheral Vascular Bioresorbable Scaffolds

By Indication:
• Target Artery Instability (TAI)
• Access Artery Injury (AAI)
• Peripheral Arterial Disease
• Arteriovenous Fistulas
• Peripheral Aneurysms
• Others

By Artery Type:
• Carotid Artery
• Fem-Pop Artery
• Iliac Artery
• Infrapop Artery

By End User:
• Hospitals
• Ambulatory Surgical Centers/Outpatients
• Cardiac Catheterization Labs

By Region:
• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East & Africa

Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.


1. Executive Summary
1.1. Global Statins Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value and Volume, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Production Output and Trade Statistics, 2018 – 2023
3.1. Global Statins Production Output, by Region, Value (US$ Bn) and Volume, 2018 – 2023
3.1.1. North America
3.1.2. Europe
3.1.3. Asia Pacific
3.1.4. Latin America
3.1.5. Middle East and Africa
4. Price Analysis, 2018 – 2023
4.1. Global Average Price Analysis by Drug Class, 2018 – 2023
4.2. Prominent Factor Affecting Statins Prices
4.3. Global Average Price Analysis by Region
5. Global Statins Market Outlook, 2018 – 2031
5.1. Global Statins Market Outlook, by Drug Class, Value (US$ Bn) and Volume, 2018 – 2031
5.1.1. Key Highlights
5.1.1.1. Astrovastatins
5.1.1.2. Fluvastatins
5.1.1.3. Lovastatins
5.1.1.4. Pravastatins
5.1.1.5. Simvastatins
5.1.1.6. Others
5.2. Global Statins Market Outlook, by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 – 2031
5.2.1. Key Highlights
5.2.1.1. Cardiovascular Disorders
5.2.1.2. Obesity
5.2.1.3. Inflammatory Disorders
5.2.1.4. Others
5.3. Global Statins Market Outlook, by End User, Value (US$ Bn) and Volume, 2018 – 2031
5.3.1. Key Highlights
5.3.1.1. Hospitals
5.3.1.2. Clinics
5.4. Global Statins Market Outlook, by Region, Value (US$ Bn) and Volume, 2018 – 2031
5.4.1. Key Highlights
5.4.1.1. North America
5.4.1.2. Europe
5.4.1.3. Asia Pacific
5.4.1.4. Latin America
5.4.1.5. Middle East & Africa
6. North America Statins Market Outlook, 2018 – 2031
6.1. North America Statins Market Outlook, by Drug Class, Value (US$ Bn) and Volume, 2018 – 2031
6.1.1. Key Highlights
6.1.1.1. Astrovastatins
6.1.1.2. Fluvastatins
6.1.1.3. Lovastatins
6.1.1.4. Pravastatins
6.1.1.5. Simvastatins
6.1.1.6. Others
6.2. North America Statins Market Outlook, by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 – 2031
6.2.1. Key Highlights
6.2.1.1. Cardiovascular Disorders
6.2.1.2. Obesity
6.2.1.3. Inflammatory Disorders
6.2.1.4. Others
6.3. North America Statins Market Outlook, by End User, Value (US$ Bn) and Volume, 2018 – 2031
6.3.1. Key Highlights
6.3.1.1. Hospitals
6.3.1.2. Clinics
6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. North America Statins Market Outlook, by Country, Value (US$ Bn) and Volume, 2018 – 2031
6.4.1. Key Highlights
6.4.1.1. U.S. Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 – 2031
6.4.1.2. U.S. Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 – 2031
6.4.1.3. U.S. Statins Market by End User, Value (US$ Bn) and Volume, 2018 – 2031
6.4.1.4. Canada Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 – 2031
6.4.1.5. Canada Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 – 2031
6.4.1.6. Canada Statins Market by End User, Value (US$ Bn) and Volume, 2018 – 2031
6.4.2. BPS Analysis/Market Attractiveness Analysis
7. Europe Statins Market Outlook, 2018 – 2031
7.1. Europe Statins Market Outlook, by Drug Class, Value (US$ Bn) and Volume, 2018 – 2031
7.1.1. Key Highlights
7.1.1.1. Astrovastatins
7.1.1.2. Fluvastatins
7.1.1.3. Lovastatins
7.1.1.4. Pravastatins
7.1.1.5. Simvastatins
7.1.1.6. Others
7.2. Europe Statins Market Outlook, by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 – 2031
7.2.1. Key Highlights
7.2.1.1. Cardiovascular Disorders
7.2.1.2. Obesity
7.2.1.3. Inflammatory Disorders
7.2.1.4. Others
7.3. Europe Statins Market Outlook, by End User, Value (US$ Bn) and Volume, 2018 – 2031
7.3.1. Key Highlights
7.3.1.1. Hospitals
7.3.1.2. Clinics
7.3.2. Attractiveness Analysis
7.4. Europe Statins Market Outlook, by Country, Value (US$ Bn) and Volume, 2018 – 2031
7.4.1. Key Highlights
7.4.1.1. Germany Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 – 2031
7.4.1.2. Germany Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 – 2031
7.4.1.3. Germany Statins Market by End User, Value (US$ Bn) and Volume, 2018 – 2031
7.4.1.4. U.K. Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 – 2031
7.4.1.5. U.K. Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 – 2031
7.4.1.6. U.K. Statins Market by End User, Value (US$ Bn) and Volume, 2018 – 2031
7.4.1.7. France Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 – 2031
7.4.1.8. France Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 – 2031
7.4.1.9. France Statins Market by End User, Value (US$ Bn) and Volume, 2018 – 2031
7.4.1.10. Italy Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 – 2031
7.4.1.11. Italy Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 – 2031
7.4.1.12. Italy Statins Market by End User, Value (US$ Bn) and Volume, 2018 – 2031
7.4.1.13. Turkey Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 – 2031
7.4.1.14. Turkey Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 – 2031
7.4.1.15. Turkey Statins Market by End User, Value (US$ Bn) and Volume, 2018 – 2031
7.4.1.16. Russia Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 – 2031
7.4.1.17. Russia Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 – 2031
7.4.1.18. Russia Statins Market by End User, Value (US$ Bn) and Volume, 2018 – 2031
7.4.1.19. Rest of Europe Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 – 2031
7.4.1.20. Rest of Europe Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 – 2031
7.4.1.21. Rest of Europe Statins Market by End User, Value (US$ Bn) and Volume, 2018 – 2031
7.4.2. BPS Analysis/Market Attractiveness Analysis
8. Asia Pacific Statins Market Outlook, 2018 – 2031
8.1. Asia Pacific Statins Market Outlook, by Drug Class, Value (US$ Bn) and Volume, 2018 – 2031
8.1.1. Key Highlights
8.1.1.1. Astrovastatins
8.1.1.2. Fluvastatins
8.1.1.3. Lovastatins
8.1.1.4. Pravastatins
8.1.1.5. Simvastatins
8.1.1.6. Others
8.2. Asia Pacific Statins Market Outlook, by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 – 2031
8.2.1. Key Highlights
8.2.1.1. Cardiovascular Disorders
8.2.1.2. Obesity
8.2.1.3. Inflammatory Disorders
8.2.1.4. Others
8.3. Asia Pacific Statins Market Outlook, by End User, Value (US$ Bn) and Volume, 2018 – 2031
8.3.1. Key Highlights
8.3.1.1. Hospitals
8.3.1.2. Clinics
8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Asia Pacific Statins Market Outlook, by Country, Value (US$ Bn) and Volume, 2018 – 2031
8.4.1. Key Highlights
8.4.1.1. China Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 – 2031
8.4.1.2. China Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 – 2031
8.4.1.3. China Statins Market by End User, Value (US$ Bn) and Volume, 2018 – 2031
8.4.1.4. Japan Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 – 2031
8.4.1.5. Japan Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 – 2031
8.4.1.6. Japan Statins Market by End User, Value (US$ Bn) and Volume, 2018 – 2031
8.4.1.7. South Korea Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 – 2031
8.4.1.8. South Korea Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 – 2031
8.4.1.9. South Korea Statins Market by End User, Value (US$ Bn) and Volume, 2018 – 2031
8.4.1.10. India Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 – 2031
8.4.1.11. India Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 – 2031
8.4.1.12. India Statins Market by End User, Value (US$ Bn) and Volume, 2018 – 2031
8.4.1.13. Southeast Asia Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 – 2031
8.4.1.14. Southeast Asia Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 – 2031
8.4.1.15. Southeast Asia Statins Market by End User, Value (US$ Bn) and Volume, 2018 – 2031
8.4.1.16. Rest of Asia Pacific Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 – 2031
8.4.1.17. Rest of Asia Pacific Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 – 2031
8.4.1.18. Rest of Asia Pacific Statins Market by End User, Value (US$ Bn) and Volume, 2018 – 2031
8.4.2. BPS Analysis/Market Attractiveness Analysis
9. Latin America Statins Market Outlook, 2018 – 2031
9.1. Latin America Statins Market Outlook, by Drug Class, Value (US$ Bn) and Volume, 2018 – 2031
9.1.1. Key Highlights
9.1.1.1. Astrovastatins
9.1.1.2. Fluvastatins
9.1.1.3. Lovastatins
9.1.1.4. Pravastatins
9.1.1.5. Simvastatins
9.1.1.6. Others
9.2. Latin America Statins Market Outlook, by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 – 2031
9.2.1. Key Highlights
9.2.1.1. Cardiovascular Disorders
9.2.1.2. Obesity
9.2.1.3. Inflammatory Disorders
9.2.1.4. Others
9.3. Latin America Statins Market Outlook, by End User, Value (US$ Bn) and Volume, 2018 – 2031
9.3.1. Key Highlights
9.3.1.1. Hospitals
9.3.1.2. Clinics
9.3.2. BPS Analysis/Market Attractiveness Analysis
9.4. Latin America Statins Market Outlook, by Country, Value (US$ Bn) and Volume, 2018 – 2031
9.4.1. Key Highlights
9.4.1.1. Brazil Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 – 2031
9.4.1.2. Brazil Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 – 2031
9.4.1.3. Brazil Statins Market by End User, Value (US$ Bn) and Volume, 2018 – 2031
9.4.1.4. Mexico Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 – 2031
9.4.1.5. Mexico Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 – 2031
9.4.1.6. Mexico Statins Market by End User, Value (US$ Bn) and Volume, 2018 – 2031
9.4.1.7. Argentina Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 – 2031
9.4.1.8. Argentina Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 – 2031
9.4.1.9. Argentina Statins Market by End User, Value (US$ Bn) and Volume, 2018 – 2031
9.4.1.10. Rest of Latin America Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 – 2031
9.4.1.11. Rest of Latin America Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 – 2031
9.4.1.12. Rest of Latin America Statins Market by End User, Value (US$ Bn) and Volume, 2018 – 2031
9.4.2. BPS Analysis/Market Attractiveness Analysis
10. Middle East & Africa Statins Market Outlook, 2018 – 2031
10.1. Middle East & Africa Statins Market Outlook, by Drug Class, Value (US$ Bn) and Volume, 2018 – 2031
10.1.1. Key Highlights
10.1.1.1. Astrovastatins
10.1.1.2. Fluvastatins
10.1.1.3. Lovastatins
10.1.1.4. Pravastatins
10.1.1.5. Simvastatins
10.1.1.6. Others
10.2. Middle East & Africa Statins Market Outlook, by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 – 2031
10.2.1. Key Highlights
10.2.1.1. Cardiovascular Disorders
10.2.1.2. Obesity
10.2.1.3. Inflammatory Disorders
10.2.1.4. Others
10.3. Middle East & Africa Statins Market Outlook, by End User, Value (US$ Bn) and Volume, 2018 – 2031
10.3.1. Key Highlights
10.3.1.1. Hospitals
10.3.1.2. Clinics
10.3.2. BPS Analysis/Market Attractiveness Analysis
10.4. Middle East & Africa Statins Market Outlook, by Country, Value (US$ Bn) and Volume, 2018 – 2031
10.4.1. Key Highlights
10.4.1.1. GCC Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 – 2031
10.4.1.2. GCC Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 – 2031
10.4.1.3. GCC Statins Market by End User, Value (US$ Bn) and Volume, 2018 – 2031
10.4.1.4. South Africa Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 – 2031
10.4.1.5. South Africa Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 – 2031
10.4.1.6. South Africa Statins Market by End User, Value (US$ Bn) and Volume, 2018 – 2031
10.4.1.7. Egypt Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 – 2031
10.4.1.8. Egypt Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 – 2031
10.4.1.9. Egypt Statins Market by End User, Value (US$ Bn) and Volume, 2018 – 2031
10.4.1.10. Nigeria Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 – 2031
10.4.1.11. Nigeria Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 – 2031
10.4.1.12. Nigeria Statins Market by End User, Value (US$ Bn) and Volume, 2018 – 2031
10.4.1.13. Rest of Middle East & Africa Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 – 2031
10.4.1.14. Rest of Middle East & Africa Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 – 2031
10.4.1.15. Rest of Middle East & Africa Statins Market by End User, Value (US$ Bn) and Volume, 2018 – 2031
10.4.2. BPS Analysis/Market Attractiveness Analysis
11. Competitive Landscape
11.1. By End User vs by Therapeutic Treatment Heatmap
11.2. Company Market Share Analysis, 2023
11.3. Competitive Dashboard
11.4. Company Profiles
11.4.1. Pfizer Inc.
11.4.1.1. Company Overview
11.4.1.2. Product Portfolio
11.4.1.3. Financial Overview
11.4.1.4. Business Strategies and Development
11.4.2. AstraZeneca plc
11.4.2.1. Company Overview
11.4.2.2. Product Portfolio
11.4.2.3. Financial Overview
11.4.2.4. Business Strategies and Development
11.4.3. Novartis International AG
11.4.3.1. Company Overview
11.4.3.2. Product Portfolio
11.4.3.3. Financial Overview
11.4.3.4. Business Strategies and Development
11.4.4. GlaxoSmithKline plc
11.4.4.1. Company Overview
11.4.4.2. Product Portfolio
11.4.4.3. Financial Overview
11.4.4.4. Business Strategies and Development
11.4.5. Merck & Co., Inc.
11.4.5.1. Company Overview
11.4.5.2. Product Portfolio
11.4.5.3. Financial Overview
11.4.5.4. Business Strategies and Development
11.4.6. Biocon
11.4.6.1. Company Overview
11.4.6.2. Product Portfolio
11.4.6.3. Financial Overview
11.4.6.4. Business Strategies and Development
11.4.7. Aurobindo Pharma Ltd
11.4.7.1. Company Overview
11.4.7.2. Product Portfolio
11.4.7.3. Financial Overview
11.4.7.4. Business Strategies and Development
11.4.8. Concord Biotech
11.4.8.1. Company Overview
11.4.8.2. Product Portfolio
11.4.8.3. Financial Overview
11.4.8.4. Business Strategies and Development
12. Appendix
12.1. Research Methodology
12.2. Report Assumptions
12.3. Acronyms and Abbreviations

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings